With the announcement that GammaDelta and Japanese biotechnology giant, Takeda Pharmaceutcals have entered a collaboration to develop the novel T cell platform, we discuss with Raj Mehta, Director of IP, Alliance Management and BD at GammaDelta what this means for the future and how the additional funding (up to US$100 million) will be used to accelerate the development of the T cell platform.

Read the full Q&A here